The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Biosimilar Monoclonal Antibody Market Research Report 2024

Global Biosimilar Monoclonal Antibody Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1714498

No of Pages : 86

Ask Your Query

Synopsis

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

The global Biosimilar Monoclonal Antibody market was valued at US$ 4509.2 million in 2023 and is anticipated to reach US$ 5726.4 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

This report aims to provide a comprehensive presentation of the global market for Biosimilar Monoclonal Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Monoclonal Antibody.

Report Scope

The Biosimilar Monoclonal Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Monoclonal Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biosimilar Monoclonal Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

By Company

  • Biocon
  • Accord Healthcare
  • AET Biotech
  • Amgen
  • Celltrion
  • Reddy's Laboratories
  • Hospira
  • 3SBio
  • Allergan
  • Alvartis
  • Segment by Type
  • Limited Dilution Method
  • Micromanipulation
  • Soft Agar Plate Method
  • Others

Segment by Application

  • Chronic & Autoimmune Diseases
  • Oncology
  • Others

Consumption by Region

  •  North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar Monoclonal Antibody Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Limited Dilution Method
1.2.3 Micromanipulation
1.2.4 Soft Agar Plate Method
1.2.5 Others
1.3 Market by Application
1.3.1 Global Biosimilar Monoclonal Antibody Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Chronic & Autoimmune Diseases
1.3.3 Oncology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar Monoclonal Antibody Market Perspective (2019-2030)
2.2 Biosimilar Monoclonal Antibody Growth Trends by Region
2.2.1 Global Biosimilar Monoclonal Antibody Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilar Monoclonal Antibody Historic Market Size by Region (2019-2024)
2.2.3 Biosimilar Monoclonal Antibody Forecasted Market Size by Region (2025-2030)
2.3 Biosimilar Monoclonal Antibody Market Dynamics
2.3.1 Biosimilar Monoclonal Antibody Industry Trends
2.3.2 Biosimilar Monoclonal Antibody Market Drivers
2.3.3 Biosimilar Monoclonal Antibody Market Challenges
2.3.4 Biosimilar Monoclonal Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar Monoclonal Antibody Players by Revenue
3.1.1 Global Top Biosimilar Monoclonal Antibody Players by Revenue (2019-2024)
3.1.2 Global Biosimilar Monoclonal Antibody Revenue Market Share by Players (2019-2024)
3.2 Global Biosimilar Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilar Monoclonal Antibody Revenue
3.4 Global Biosimilar Monoclonal Antibody Market Concentration Ratio
3.4.1 Global Biosimilar Monoclonal Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar Monoclonal Antibody Revenue in 2023
3.5 Biosimilar Monoclonal Antibody Key Players Head office and Area Served
3.6 Key Players Biosimilar Monoclonal Antibody Product Solution and Service
3.7 Date of Enter into Biosimilar Monoclonal Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar Monoclonal Antibody Breakdown Data by Type
4.1 Global Biosimilar Monoclonal Antibody Historic Market Size by Type (2019-2024)
4.2 Global Biosimilar Monoclonal Antibody Forecasted Market Size by Type (2025-2030)
5 Biosimilar Monoclonal Antibody Breakdown Data by Application
5.1 Global Biosimilar Monoclonal Antibody Historic Market Size by Application (2019-2024)
5.2 Global Biosimilar Monoclonal Antibody Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biosimilar Monoclonal Antibody Market Size (2019-2030)
6.2 North America Biosimilar Monoclonal Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilar Monoclonal Antibody Market Size by Country (2019-2024)
6.4 North America Biosimilar Monoclonal Antibody Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar Monoclonal Antibody Market Size (2019-2030)
7.2 Europe Biosimilar Monoclonal Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilar Monoclonal Antibody Market Size by Country (2019-2024)
7.4 Europe Biosimilar Monoclonal Antibody Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Monoclonal Antibody Market Size (2019-2030)
8.2 Asia-Pacific Biosimilar Monoclonal Antibody Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilar Monoclonal Antibody Market Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilar Monoclonal Antibody Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar Monoclonal Antibody Market Size (2019-2030)
9.2 Latin America Biosimilar Monoclonal Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilar Monoclonal Antibody Market Size by Country (2019-2024)
9.4 Latin America Biosimilar Monoclonal Antibody Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Monoclonal Antibody Market Size (2019-2030)
10.2 Middle East & Africa Biosimilar Monoclonal Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilar Monoclonal Antibody Market Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilar Monoclonal Antibody Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biocon
11.1.1 Biocon Company Detail
11.1.2 Biocon Business Overview
11.1.3 Biocon Biosimilar Monoclonal Antibody Introduction
11.1.4 Biocon Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.1.5 Biocon Recent Development
11.2 Accord Healthcare
11.2.1 Accord Healthcare Company Detail
11.2.2 Accord Healthcare Business Overview
11.2.3 Accord Healthcare Biosimilar Monoclonal Antibody Introduction
11.2.4 Accord Healthcare Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.2.5 Accord Healthcare Recent Development
11.3 AET Biotech
11.3.1 AET Biotech Company Detail
11.3.2 AET Biotech Business Overview
11.3.3 AET Biotech Biosimilar Monoclonal Antibody Introduction
11.3.4 AET Biotech Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.3.5 AET Biotech Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Biosimilar Monoclonal Antibody Introduction
11.4.4 Amgen Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.4.5 Amgen Recent Development
11.5 Celltrion
11.5.1 Celltrion Company Detail
11.5.2 Celltrion Business Overview
11.5.3 Celltrion Biosimilar Monoclonal Antibody Introduction
11.5.4 Celltrion Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.5.5 Celltrion Recent Development
11.6 Reddy's Laboratories
11.6.1 Reddy's Laboratories Company Detail
11.6.2 Reddy's Laboratories Business Overview
11.6.3 Reddy's Laboratories Biosimilar Monoclonal Antibody Introduction
11.6.4 Reddy's Laboratories Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.6.5 Reddy's Laboratories Recent Development
11.7 Hospira
11.7.1 Hospira Company Detail
11.7.2 Hospira Business Overview
11.7.3 Hospira Biosimilar Monoclonal Antibody Introduction
11.7.4 Hospira Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.7.5 Hospira Recent Development
11.8 3SBio
11.8.1 3SBio Company Detail
11.8.2 3SBio Business Overview
11.8.3 3SBio Biosimilar Monoclonal Antibody Introduction
11.8.4 3SBio Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.8.5 3SBio Recent Development
11.9 Allergan
11.9.1 Allergan Company Detail
11.9.2 Allergan Business Overview
11.9.3 Allergan Biosimilar Monoclonal Antibody Introduction
11.9.4 Allergan Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.9.5 Allergan Recent Development
11.10 Alvartis
11.10.1 Alvartis Company Detail
11.10.2 Alvartis Business Overview
11.10.3 Alvartis Biosimilar Monoclonal Antibody Introduction
11.10.4 Alvartis Revenue in Biosimilar Monoclonal Antibody Business (2019-2024)
11.10.5 Alvartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock